NLRP3 and Neonatal onset: To this point, we confirmed the improved IL-1β inhibitory potency of compound A over reference compound MCC950 in primary PBMC from a CAPS-patient diagnosed with Familial Cold Auto-inflammatory Syndrome (FCAS with L355P mutation in human NLRP3) and Neonatal Onset Multisystem Inflammatory Disease (NOMID with D305N mutation in human NLRP3) (Figs. 5L and EV4E).